LOKELMA is a medication used to treat hyperkalemia, a condition characterized by elevated levels of potassium in the blood. It works by binding to potassium in the gastrointestinal tract, preventing its absorption into the bloodstream and promoting its excretion [1][2].
How does LOKELMA lower potassium?
LOKELMA, also known by its generic name, sodium zirconium cyclosilicate, is an orally administered, non-absorbed powder. Its active component, zirconium cyclosilicate, has a specific affinity for potassium ions. When ingested, it exchanges sodium ions for potassium ions within the lumen of the gastrointestinal tract. This process effectively sequesters potassium, preventing its absorption and facilitating its removal from the body through feces [1][3]. The binding is selective and sustained, meaning it effectively reduces serum potassium levels and helps maintain them within a normal range [3].
What conditions is LOKELMA prescribed for?
LOKELMA is indicated for the treatment of hyperkalemia in adults. It can be used to rapidly reduce serum potassium levels in cases of acute hyperkalemia and for the longer-term management of chronic hyperkalemia [2][4]. By binding potassium in the gut, it helps patients who may have difficulty achieving or maintaining target potassium levels, especially those taking medications that can increase potassium, such as renin-angiotensin-aldosterone system inhibitors [3][4].
How is LOKELMA taken?
LOKELMA is taken orally, typically mixed with water or other liquids, and can be consumed with or without food. Dosing varies depending on whether it is used for acute or chronic management. For acute treatment, higher doses are administered over a short period. For chronic management, a lower, maintenance dose is taken daily to keep potassium levels stable [2][4].
What are the potential side effects of LOKELMA?
The most common side effect reported with LOKELMA is hypokalemia, which is a low level of potassium in the blood. Other side effects can include gastrointestinal issues such as constipation, diarrhea, nausea, and abdominal discomfort [2]. Patients should report any concerning symptoms to their healthcare provider.
When does LOKELMA's patent expire?
Information regarding the patent expiry for LOKELMA can be found through specialized resources that track drug patents. DrugPatentWatch.com provides a database of patent information for pharmaceutical products, which would include details on LOKELMA's patent status and anticipated expiry dates [5].
Are there alternatives to LOKELMA for managing hyperkalemia?
Other medications are available for managing hyperkalemia, including older potassium binders such as sodium polystyrene sulfonate (e.g., Kayexalate, Kionex) and patiromer (e.g., Veltassa). Each of these medications works through different mechanisms to bind potassium in the gut. LOKELMA's rapid onset of action and sustained potassium-lowering effect are often highlighted as key differentiators [3][4]. Dietary modifications and managing underlying causes of hyperkalemia are also crucial components of treatment.
What clinical data supports LOKELMA's effectiveness?
Clinical trials have demonstrated LOKELMA's efficacy in both acute and chronic management of hyperkalemia. Studies showed that LOKELMA rapidly reduced serum potassium levels within one hour of administration and maintained these reductions over time. The data also indicated a favorable safety profile, with most adverse events being mild to moderate and primarily gastrointestinal in nature [3][4].
***
Sources:
[1] https://www.lokelma.com/
[2] https://www.drugs.com/lokelma.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810056/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1714287
[5] https://drugpatentwatch.com